Title: Immunohistochemical Profile in Lung Carcinoma
Authors: Niyatha Balakrishnan, C. R. Jyothi
DOI: https://dx.doi.org/10.18535/jmscr/v6i9.177
Abstract
Introduction: Small biopsies obtained by bronchoscopy are commonly used for diagnosis of lung malignancies. The emergence of treatments for lung carcinoma with differential efficacy and toxicity between subtypes has highlighted the importance of specific pathologic subtyping. The use of immunohistochemistry (IHC) has been well documented as an important ancillary tool in sub classifying lung carcinomas.
Objectives: This study is aimed to assess the expression of a panel 3 IHC markers - CK5/6, p63 and TTF-1, in 39 cases of lung carcinomas
Materials & Methods: This was a cross sectional study done over a period of 18 months in bronchial biopsy specimens of histologically proven lung carcinoma
Observations: It was observed that CK5/6 and p63 were 100% senisitive and specific for squamous cell carcinomas, if unquantified reactivities were consiered the specificity of p63 reduced to 83% and TTF-1 had 100% sensitivity and specificity in diagnosing adenocarcinoma, but if diffuse TTF-1 positivity was considered the sensitivity reduced to 66.6%.
TTF-1/p63 immuno profile showed no overlap when squamous cell carcinomas and small cell lung carcinomas were compared.
Conclusion: 3 panel IHC markers, CK5/6, p63 and TTF-1 when used together and interpreted correctly can be of help for the final diagnosis even in cases in which the morphology is unclear.
Keywords: Immunohistochemistry; CK5/6; p63; TTF-1; Squamous cell carcinoma; Adenocarcinoma; Small cell carcinoma.
References
- Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer. 2003;88 (8):1229–1233.
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin.2010;60(5):277–300.
- Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: International Agency for Research on Cancer,2015
- Argon A et al.The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.Turk Patoloji Derg 2015;31:81-88.
- Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of animmunohistochemical panel containing TTF-1, napsin A, p63 and CK5/6. Am J Surg Pathol 2011;35:15–25.
- Terry J, Leung S, Laskin J, Leslie K, Gown A, Ionescu D. Optimal immunohisto-chemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010; 34(12):1805–1811.
- Wei Zhao et al. ΔNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int J ClinExpPathol 2014;7(7):4247-4253.
- Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007;15:415–20.
- Folpe AL, Gown AM, Lamps LW, et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 1999;12:5–8.
- Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000;36:8–16.